Search research articles
Contact Us
Filters
Showing results (11-20 of 56) with videos related to
Page
of 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts
Robert J Kinders, Melinda Hollingshead, Sonny Khin, et al.
Breast Cancer Research and Treatment
|
November 10, 2017
Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials
Filipa Lynce, Matthew J Blackburn, Ling Cai, et al.
Journal of Hematology & Oncology
|
February 6, 2015
Notch1 phenotype and clinical stage progression in non-small cell lung cancer
Dat Nguyen, Larry Rubinstein, Naoko Takebe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 20, 2008
Individual patient data analysis to assess modifications to the RECIST criteria
Jan Bogaerts, Robert Ford, Dan Sargent, et al.
Plos One
|
October 27, 2011
Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells
Jiuping Ji, Robert J Kinders, Yiping Zhang, et al.
The New England Journal of Medicine
|
March 5, 2005
Risks and benefits of phase 1 oncology trials, 1991 through 2002
Elizabeth Horstmann, Mary S McCabe, Louise Grochow, et al.
Journal of Hematology & Oncology
|
May 27, 2021
TET2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models
Sherry X Yang, Melinda Hollingshead, Larry Rubinstein, et al.
The Oncologist
|
June 2, 2018
A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas
Robert Meehan, Shivaani Kummar, Khanh Do, et al.
Cancer Science
|
November 9, 2017
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials
Akihiro Hirakawa, Kan Yonemori, Fumie Kinoshita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2016
Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual
Holly A Massett, Grace Mishkin, Larry Rubinstein, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 56) with videos related to
Sort By:
Page
of 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts
Robert J Kinders, Melinda Hollingshead, Sonny Khin, et al.
Breast Cancer Research and Treatment
|
November 10, 2017
Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials
Filipa Lynce, Matthew J Blackburn, Ling Cai, et al.
Journal of Hematology & Oncology
|
February 6, 2015
Notch1 phenotype and clinical stage progression in non-small cell lung cancer
Dat Nguyen, Larry Rubinstein, Naoko Takebe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 20, 2008
Individual patient data analysis to assess modifications to the RECIST criteria
Jan Bogaerts, Robert Ford, Dan Sargent, et al.
Plos One
|
October 27, 2011
Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells
Jiuping Ji, Robert J Kinders, Yiping Zhang, et al.
The New England Journal of Medicine
|
March 5, 2005
Risks and benefits of phase 1 oncology trials, 1991 through 2002
Elizabeth Horstmann, Mary S McCabe, Louise Grochow, et al.
Journal of Hematology & Oncology
|
May 27, 2021
TET2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models
Sherry X Yang, Melinda Hollingshead, Larry Rubinstein, et al.
The Oncologist
|
June 2, 2018
A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas
Robert Meehan, Shivaani Kummar, Khanh Do, et al.
Cancer Science
|
November 9, 2017
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials
Akihiro Hirakawa, Kan Yonemori, Fumie Kinoshita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2016
Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual
Holly A Massett, Grace Mishkin, Larry Rubinstein, et al.
Page
of 6